Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature. (21st May 2020)

• Record Type: Journal Article
• Authors: Zingg, Sandra; Nicoletti, G Jacopo; Kuster, Sabine; Junker, Milena; Widmer, Andreas; Egli, Adrian; Hinic, Vladimira; Sendi, Parham; Battegay, Manuel; Bättig, Veronika; Khanna, Nina; Tschudin-Sutter, Sarah
• Is Part Of: Open forum infectious diseases. Volume 7:Number 6(2020)
• Publication Date: 2020-05-21
• Subjects: carbapenemase -- case series -- cefiderocol -- drug-resistant gram-negatives -- review; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofaa185
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Cefiderocol is a new siderophore cephalosporin with activity against carbapenem-resistant gram-negative bacteria. Data on its clinical efficacy are limited to complicated urinary tract infections. We present a series of 3 patients successfully treated with cefiderocol for complicated health care–associated infections and review published case reports.